All Stories

Sotio takes up option on ADCs, while Boehringer inks GPCR discovery pact

Sotio Biotech is pushing deeper into bispecific antibody-drug conjugates, taking up its option to use Synaffix’s technology in two candidates. The Czech biotech disclosed the update on the same day as Salipro Biotech revealed a partnership with Boehringer Ingelheim.

Mar 13, 2025 - 23:23
 0
Sotio takes up option on ADCs, while Boehringer inks GPCR discovery pact
Sotio Biotech is pushing deeper into bispecific antibody-drug conjugates, taking up its option to use Synaffix’s technology in two candidates. The Czech biotech disclosed the update on the same day as Salipro Biotech revealed a partnership with Boehringer Ingelheim.
Read More

Tags:

Previous Article

Hologen AI commits up to $430M to help take MeiraGTx's Parkinson's gene therapy ...

Next Article

ImmunoPrecise teases $10M ADC, bispecific collab with major biotech

Related Posts

Entrada's 2-year ordeal ends as FDA lifts hold on DMD drug

Entrada's 2-year ordeal ends as FDA lifts hold on DMD drug

Feb 25, 2025  0

Tandem Diabetes Care insulin-dosing algorithm nets FDA clearance for Type 2 diabetes

Tandem Diabetes Care insulin-dosing algorithm nets FDA ...

Feb 25, 2025  0

Viracta Therapeutics hits end of the line, laying off all workers and winding down

Viracta Therapeutics hits end of the line, laying off a...

Feb 9, 2025  0